Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level of lung alveolar macrophages (AM) and interstital macrophages (IM) in MMTV-HER2 and wildtype early stage (16-week) or late stage (32-week) mice.

ABSTRACT: Disseminated cancer cells reside in the lung alveolar niche where they are exposed to interactions with alveolar macrophages. Here we report singe-cell RNA-sequencing data of lung macrophages from MMTV-HER2 mice at the early stage (16-weeks) harboring single dormant cancer cells and late stage mice (32-weeks harboring metastatic lesions, as well as wildtype control mice. We discovered alveolar macrophage and interstitial macrophage subsets that change in expression profile and frequency between stages. We find majority of the AMs are homeostatic in phenotype, and emergence of inflammatory AM subsets in late-stage MMTV-HER2 mice.

ORGANISM(S): Mus musculus

PROVIDER: GSE278454 | GEO | 2024/10/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile at single cell level of lung alveolar macrophages (AM) and interstital macrophages (IM) in MMTV-HER2 and wildtype early stage (16-week) or late stage (32-week) mice.

Project description:Gene expression profile at single cell level of lung alveolar macrophages (AM) and interstital macrophages (IM) in MMTV-HER2 and wildtype early stage (16-week) or late stage (32-week) mice.

| PRJNA1169196 | ENA

Comparative analysis of 10 week and 5 week Bitransgenic mice (LH mouse crossed with MMTV-neu mouse)

Project description:To identify genes that may facilitate early steps of ErbB2/Neu-mediated mammary tumorigenesis, we performed comparative microarray analysis of 5- and 10-week bitransgenic mammary glands (LHxMMTV-neu) in triplicate. Keywords: transgenic mouse, erbB2, MMTV-neu, HER2, mammary tumor, breast cancer

2006-01-01 | GSE3501 | GEO

RNA sequencing analysis of MED1-overexpression induced transcription changes in HER2+ mammary tumors

Project description:The goal of this study is to reveals MED1-overexpression induced gene expression changes in HER2+ breast cancers Total RNA from paired mouse MMTV-HER2 and MMTV-HER2/MMTV-MED1 mammary tumors were prepared using RNA easy mini kit for RNA-Seq analysis the gene expression changes.

2021-04-21 | GSE148922 | GEO

miRNA profiling of late stage metastatic Her2+ breast cancer

Project description:We have assayed differential miRNA expression between late stage (stage IV) metastatic Her2+ and Her2- breast cancer.

2010-04-29 | GSE20066 | GEO

Mus musculus strain:FVB | isolate:Mammary tumor

Project description:RNA-Seq on MMTV-HER2 and MMTV-HER2 DNPH1-/- mammary tumors

| PRJNA753535 | ENA

The effect of co-culture on MMTV-HER2 early lesion or primary tumor cell and alveolar macrophages [bulk RNA-seq]

Project description:Disseminated cancer cells reside in the lung alveolar niche where they are exposed to interactions with alveolar macrophages. Here we report bulk RNA-sequencing data from co-cultured MMTV-HER2 mammary early lesion cells or mammary primary tumor cells cultured with lung alveolar macrophages. We discovered reciprocal regulation between mammary cells and alveolar macrophages, where early lesion cells instruct alveolar macrophages to maintain an anti-tumor phenotype and alveolar macrophages activate an epithelial to mesenchymal program in early lesion cells. Coveresely, primary tumor cells activate inflammatory prorgams in alveolar macrophages, while alveolar macrophages are not able to activate growth restriction programs in primary tumor cells. Receptor-ligand analysis highlighted two known pathways invovled in quiencesce, namely the TGF-beta pathway and the OSM pathway.

2024-09-30 | GSE278443 | GEO

miRNA profiling of late stage metastatic Her2+ breast cancer

Project description:We have assayed differential miRNA expression between late stage (stage IV) metastatic Her2+ and Her2- breast cancer. 4 late stage metastatic Her2- samples were compared to 3 late stage metastatic Her2+ samples. There are 4 within array replicates for each sample.

2010-04-29 | E-GEOD-20066 | biostudies-arrayexpress

FiTAc-seq analysis of PDX 14-07 and MMTV-rtTA/tetO/Her2 tumors treated with abemaciclib

Project description:We measured changes in H3K27ac after treatment of PDX 14-07 or MMTV-rtTA/tetO-Her2 tumors implanted in nude mice with abemaciclib

2020-09-03 | GSE157384 | GEO

Mechanisms associated with systemic effects of cancer

Project description:Cancer is considered as a disease of a specific organ, but its effects are felt throughout the body. The systemic effects of cancer can lead to weakness in muscles and heart, which hastens cancer-associated death. miR-486 is a myogenic microRNA and its reduced expression in skeletal muscle is observed in muscular dystrophy. Muscle-specific transgenic expression of miR-486 using muscle creatine kinase promoter (MCK-miR-486) partially rescues skeletal muscle defects in muscular dystrophy animal models. We had previously demonstrated reduced circulating and skeletal muscle levels of miR-486 in several cancer types and lower miR-486 levels correlated with skeletal muscle defects and functional limitations in mammary tumor models. Therefore, skeletal muscle defects induced by cancer could resemble defects observed in various dystrophies, which could be reversed through skeletal muscle expression of miR-486. We performed functional limitations studies and biochemical analysis of skeletal muscles of MMTV-Neu transgenic mice that mimic HER2+ breast cancer and MMTV-PyMT transgenic mice that mimic luminal subtype B breast cancer and these mice crossed to MCK-miR-486 transgenic mice. miR-486 significantly prevented tumor-induced reduction in muscle contraction force, grip strength, and rotarod performance in MMTV-Neu, but not in MMTV-PyMT mice. In MMTV-Neu model, miR-486 reversed several of the cancer-induced changes in skeletal muscle including loss of p53, phospho-AKT, and phospho-laminin alpha 2 (LAMA2) and gain of phosphorylation of the pre-mRNA processing factor hnRNPA0 and the splicing factor SRSF10. LAMA2 is a part of the dystrophin-associated glycoprotein complex, and its loss-of-function mutation is associated with congenital muscular dystrophy. Thus, similar to muscular dystrophy, miR-486 has the potential to reverse skeletal muscle defects and cancer burden in select cancer types.

2022-05-19 | PXD028554 | Pride

Project description:We previously identified a novel SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for Hunk in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer. Together, these findings establish a role for Hunk in metastasis and an in vivo function for this kinase. Hunk-deficient animals were crossed to mice harboring an MMTV-c-myc transgene (Leder et al., 1986). Hunk heterozygous, MMTV-c-myc mice were backcrossed to Hunk heterozygous animals. MMTV-c-myc female animals of each Hunk genotype were mated twice, then monitored twice weekly for mammary tumors. Mice possessing tumors with a maximum diameter of 20 mm were sacrificed and organs were examined at necropsy. Tumor nodules were identified by examination of organs through a Leica Wild MZ8 dissection microscope.

2009-12-31 | E-GEOD-14226 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data